Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Exosomes in atherosclerosis: performers, bystanders, biomarkers, and therapeutic targets

Wang C., Li Z., Liu Y., Yuan L.

Narrative Review on Systemic / IV, published in Theranostics (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Theranostics (2021)
Reported sample size
—
Source database
Europe PMC
PMID
33664877
PMCID
PMC7914371
DOI
10.7150/thno.56035
Citations
160

Abstract (original English)

Exosomes are nanosized lipid vesicles originating from the endosomal system that carry many macromolecules from their parental cells and play important roles in intercellular communication. The functions and underlying mechanisms of exosomes in atherosclerosis have recently been intensively studied. In this review, we briefly introduce exosome biology and then focus on advances in the roles of exosomes in atherosclerosis, specifically exosomal changes associated with atherosclerosis, their cellular origins and potential functional cargos, and their detailed impacts on recipient cells. We also discuss the potential of exosomes as biomarkers and drug carriers for managing atherosclerosis.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Blood PlateletsMacrophagesHumansDiabetes MellitusObesityMicroRNAsDrug CarriersRisk FactorsModels, CardiovascularAtherosclerosis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research